anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For clonidine, the regimen is designed to be equipotent with dexmedetomidine based on known pharmacokinetics and pharmacodynamics. The chosen regimen is similar to that currently used in many UK ICUs as part of routine 'off label' practice. Clonidine will be up and down titrated against sedation targets set by clinical staff and reviewed at regular intervals, and at least daily. No loading dose will be administered. The starting dose will be 1.0µg.kg-1.hour-1 titrated to a maximum dose of 2 µg.kg-1.hour-1. Lower starting doses will be used at clinical discretion for patients with cardiovascular instability.
Overactive bladder is a common sequelae of long-term bladder outlet obstruction in men. Unfortunately, it does not often resolve after treatment of the obstruction (transurethral resection of the prostate). These patients are usually started empirically on alpha-blockers or occasionally anticholinergic agents, former used to treat enlarged prostate medically, and latter, to treat overactive bladder. We hypothesize that these patients would be significantly improved with a long-acting anticholinergic agent such as long acting Fesoterodine or Toviaz.

Earlier studies have shown that anticholinergic drugs seem to have a beneficial effect on symptoms of patients with bladder outlet obstruction and overactive bladder. In addition, anticholinergic drug Toviaz is not associated with increased incidence of complication like acute urinary retention, a state where patient is unable to empty the bladder as an adverse effect of the drug.

A large proportion of our patients that are undergoing treatment for bladder outlet obstruction also have overactive bladder. We propose an open label trial to evaluate the efficacy of Toviaz (fesoterodine) 4mg to 8 mg in patients that have continued symptoms of overactive bladder one month following transurethral resection of the prostate. Toviaz is an antimuscarinic and anticholinergic agent, and is a newer formulation of Detrol. Patients with overactive bladder on urodynamic test preoperatively will be considered. If these patients continue to have symptoms at the one-month post-operative visit, they will be enrolled into the study. We expect a total of 25 patients to be enrolled within 4 months. All patients will receive Toviaz 4mg to 8 mg. The patients will be followed at 3 months post-op, 4 months post-op, and 7 months post-op. At each post-op visit, the patients will fill out an AUA symptom score questionnaire, have noninvasive uroflowmetry performed, and have a post-void residual measured by bladder scan. Using standard statistical analysis, we will see if there is a difference in symptoms, post-void residual, or maximum flow rate between baseline and 7 months post-op. We will continue the study to evaluate long-term efficacy, dropout rate, and complications. An FDA approved flexible dosing regimen will be allowed for the duration of the study.
An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects. The present invention includes 4a,9-dihydroxy-7a-(hydroxymethyl)-3 -methyl-2,3,4,4a,5,6-hexahydro-1 H-4, 12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one (UMB 425) a 5,14-bridged morphinan-based orvinol precursor, along with analogs of morphine, dihydromorphine, hydromorphone, codeine, dihydrocodeine, hydrocodone and ethylmorphine. Although UMB 425 lacks δ-specific motifs, conformationally sampled pharmacophore models for μ and δ receptors predict it to have efficacy similar to morphine at μ receptors and similar to naltrexone at δ receptors, due to the compound sampling conformations in which the hydroxyl moiety interacts with the receptors similar to orvinols. UMB 425 exhibits a mixed μ agonist/δ antagonist profile as determined in receptor binding. UMB 425 has mixed μ agonist/δ antagonist properties in vitro that translate to reduced tolerance liabilities in vivo.
Hepatic arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. 12/8 mg (weight ≥ 60kg / \< 60 kg) of Lenvatinib once daily after HAIC. PD-1 inhibitors injection intravenously or percutaneously before 24h of HAIC every 4 week.
The application provides a strontium-doped bioactive glass/gelatin nanofiber microsphere and a preparation method and application thereof, and relates to the technical field of biological scaffolds. The preparation method of the application integrates the strontium (Sr) -doped Bioactive Glass Nanospheres (BGNs) into the nanofiber structure of the Gelatin Nanofiber Microsphere (GNMs) to synthesize an innovative injectable Sr-BGNs/GNMs stent. The design mimicking the natural bone extracellular matrix enhances the mechanical properties of the scaffold and effectively controls the sustained release of strontium ions, thereby promoting proliferation of PDLSCs and BMSCs, osteogenic differentiation and ECM secretion, and enhancing angiogenesis of endothelial cells. Sr-BGNs/GNMs can significantly promote osteogenesis and angiogenesis. The adjustable degradation kinetics of the scaffold optimizes the long-term release and regeneration promotion of Sr  2+  in vivo, matching the rate of periodontal regeneration, thereby promoting the regeneration of functional periodontal tissue under osteoporotic conditions. Therefore, sr-BGNs/GNMs is expected to be a candidate material for advancing periodontal regeneration strategies.
There has been a years-long national shortage of several blood types in the U.S., including in the Geisinger community. Previously, the study team collaborated with Miller Keystone, where Geisinger refers patients who wish to donate blood and from whom Geisinger receives blood for clinical purposes, on an outreach study to encourage blood donation in patients with needed blood types. The study demonstrated that, compared to a no-message control group, patient portal messages sent to patients with needed blood types increase patients' likelihood of attending donation appointments. However, results were ambiguous with respect to which of two message versions was most effective. One version, which stated that the patient had a needed blood type (blood-type message), caused a numerically, but not significantly, higher number of patients who attended appointments compared to the other version, which did not state that the patient had a blood type in need but rather informed the recipient of a general blood shortage (no-blood-type message).

Because Miller Keystone particularly values reaching new donors, the team ran a preregistered exploratory analysis to test whether the messages were differently effective for new donors compared to those who had previously donated at a Miller Keystone site. There was a significant interaction between previous donor status (previous donor, previous non-donor) and message type, such that previous non-donors were relatively more responsive to the blood-type message, while previous donors were more responsive to the no-blood-type message. However, the groups were uneven with respect to the number of patients that had previously donated. Moreover, when the analysis was limited to patients who opened their messages, this interaction effect disappeared: blood-type messages were still most effective in previous non-donors, and there was no difference in message effectiveness among previous donors. These follow-up analyses, and the unevenness of previous donors across groups, call into question the robustness of the interaction effect.

The present study will again test whether the blood-type message is more effective than the no-blood-type message for patients with needed blood types overall, and separately for previous donors and non-donors. Messages will be sent via email rather than via patient portal in the present study. Randomization will occur at the email-address level to one of the two message types to ensure everyone using the same email address receives the same message (although each patient will be sent an individualized message with their name; there will be no no-contact control condition this time). Email addresses will be excluded if they are shared by patients with different blood types. Randomization will be stratified by whether all patients using the same email address are previous donors or not (email addresses shared by previous donors and non-donors will be excluded).
During 2-3 days this group receives three placebo treatments with an identically looking laser, which in contrast submits only red colored light. The therapy is also carried out by a specially trained breastfeeding consultant.
Pharmacologically active phenylalanyl-prolyl peptides (I) are new (where X is the N-terminal amino acid phenylalanine (opt. substd.); Pro stands for proline (opt. substd.); and A, B, C, D... are any desired amino acid). The new peptides have pharmacological (esp. antipsychotic, neuroleptic, tranquilising) activity, and in some cases have opiate activity and in others are opiate-inactive. In comparison with the peptides disclosed in DE2921216, the new peptides have an improved ability to cross the blood-brain barrier giving improved permeation of the CNS. Apart from their therapeutic use, the new peptides may be coupled with thyroglobulin or other macromolecular proteins to give antigens which can be used for the prodn. of antibodies against the new peptides. The antibodies can be used for the analysis of the peptides in tissues and body fluids. The peptides themselves can be used as functional diagnostic agents.
The objective of this study was to determine the association between acute and chronic pain and various economic and quality-of-life outcomes. The study sample was drawn from the World Trade Center Health Registry. Both acute and chronic pain were measured in 2020-2021. Logistic regression models were constructed to determine the odds of several economic and quality-of-life variables: early retirement, low household income, decline in household income, quality of life, and not working due to health. Those who had extreme pain in the last four weeks that interfered with normal work had 3.12 (95% confidence interval (CI): 2.36, 4.39) times the odds of early retirement, 5.34 (95% CI: 3.47, 8.21) times the odds of having a household income below USD 50,000, 2.56 (95% CI: 1.51, 4.33) times the odds of having an income decrease, and 14.4 (95% CI: 11.3, 18.3) times the rate of poor health days compared to those with no pain. Similar results were found for chronic pain. The detrimental effects of pain may influence multiple facets of a patient's life, and both financial and overall well-being may diminish even several years after a pain diagnosis.
The present invention relates to a cosmetic composition, which contains a natural fullerene, and a method for manufacturing same. The present invention provides a cosmetic composition containing a natural fullerene, which is extracted from a shungite mineral. In addition, the present invention comprises: a process of preparing a natural fullerene; and a process of mixing the natural fullerene with a base of a cosmetic composition. The process of preparing a natural fullerene comprises: a first step of pulverizing a shungite mineral containing a carbon component; a second step of extracting and separating a carbon component from the pulverized shungite mineral; and a third step of heat-treating the separated carbon component at a temperature of 850 to 3,000°C in a boron atmosphere. According to the present invention, a natural fullerene is extracted from a shungite mineral with a high extraction rate, with a less ash component, and with a hollow structure (porosity) to the maximum extent possible. Accordingly, the present invention has strong anti-oxidant and bactericidal properties and simultaneously, is capable of reducing an activity of active oxygen and melanin, and has the effects of anti-aging, anti-wrinkle, atopic treatment and prevention and wound healing as well as a high productivity and an economic efficiency.
A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that doxepin is not approved for use in treating bipolar depression.

It should be noted that doxepin is not approved for use in treating any indications in the pediatric population.

The once a day dosage regimen of doxepin in patients with intercurrent illness or patients taking other medications should be carefully adjusted. This is especially important in patients receiving other medications with anticholinergic effects.
This study will be performed to verify the reliability of the functional tests for individuals with back pain. A study in which individuals with back pain will be assessed on the first day and after the interval of seven days. They should perform the 6-minute walk test and answer some questionnaires such as the Roland Morris - disability questionnaire, the IPAQ - physical activity level questionnaire and Numeric Rating Scale, after the tests will be performed Timed 10-Meter Walk Test and 30 Second Sit to Stand Test. To avoid a random error, a minimum sample size of 30 participants is required. For statistical analysis, Shapiro-Wilk test will be used for data normalization and the reliability between measurements will be calculated through do Intraclass Correlation Coefficients, standard error of measurement and Minimal Detectable Change. There were no studies in the literature and recorded in the Clinical Trials that evaluated the reliability of these tests for individuals with chronic low back pain.
Chronic pain is a substantial health problem with a high prevalence of comorbid depression. To understand the link between chronic pain and depression, cognitive factors including pain catastrophising and pain self-efficacy have been theorised as significant contributing variables. There is relatively strong evidence that pain catastrophising mediates the relationship between pain severity and depression symptoms. There is also emerging evidence that the mediation role of pain catastrophising may vary as a function of pain self-efficacy. However, it is unknown whether this model will apply in a tertiary pain clinic sample. Thus, this study aimed to examine the respective moderating and mediating roles of pain self-efficacy and pain catastrophising on the association between pain severity and depressive symptoms in a large clinical sample of Australian adults living with chronic pain. Participants (n = 1195) completed all questionnaire measures prior to their first appointments at one tertiary pain service. As expected, the PROCESS path analysis showed that pain catastrophising mediated the relationship between pain severity and depressive symptoms. Further, there was support for the moderating effect of pain self-efficacy; as pain self-efficacy decreased, the relationship strengthened between both pain severity and pain catastrophising, as well as pain catastrophising and depressive symptoms. These findings may have important clinical implications including how relationships between these factors may be considered in the provision of care for those with chronic pain. Notably, these measures could be used in triaging processes to inform treatment decisions.
The present invention relates to vanishing cream for whitening skin and to a method for producing the same, wherein the vanishing cream contains arbutin, niacinamide, vitamin C, and a vegetable extract extracted from a plant. By means of the present invention, by containing arbutin, the generation of melanin pigments which are the cause of ephelides and freckles can be strongly controlled, so that skin can become transparent and skin darkness, freckles, ephelides, and skin roughness can be alleviated. By containing niacinamide, the movement of melanin from melanocyte to keratinocyte is reduced, thereby assisting in skin whitening that maintains one′s clear skin. By containing vitamin C, the activity of tyrosinase which is a melanin pigment-generating enzyme can be controlled so that skin can be effectively whitened. By containing a tomato callus cultured extract as a vegetable extract, by means of anti-acidification and collagen synthesis effects, aging is prevented and the generation of blemishes is controlled, so that skin can be whitened. By containing a mulberry root extract as a vegetable extract, excellent melanin generation controlling effects, skin whitening effects, and moisturizing effects can be ensured, and the activity of tyrosinase can be controlled so that harmful oxygen can be removed and controlled to not be activated and skin aging can be prevented. By containing a mulberry stem and root extract as a vegetable extract, excellent tyrosinase inhibiting functions can be ensured so that skin can be effectively whitened.
<P>PROBLEM TO BE SOLVED: To provide a technique to inhibit the growth of the capillary endothelial cells of the adrenal cortex.  <P>SOLUTION: The medicine is a growth inhibitor for the growth of the capillary endothelial cells of the adrenal cortex containing an antibody which specifically bonds to a polypeptide and inhibits the ability of the polypeptide to stimulate the growth of the capillary endothelial cells of the adrenal cortex. The peptide has an amino acid sequence shown in figure 266 (sequence no.: 371) with or without a signal peptide and an amino acid sequence encoded by a nucleic acid molecule deposited under ATCC accession No. 203091 with or without a signal peptide.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR during any visit to a family practice or pediatric clinic (including both preventive care and sick visits, excluding prenatal and postpartum visits). The algorithm will be embedded in the EHR. In most cases, when a normal BP \<90% and \<120/80 mm Hg is entered, no alerts will be triggered. In some cases, clinical staff may receive up to two alerts, either to measure height or to repeat a first elevated BP reading. In cases with confirmed elevated BP measures, providers will receive a single CDS message summarizing that patient's current BP status and recommending specific clinical actions.
Disordered eating behaviors consistently associated with emotion regulation difficulties. However, most studies have focused on affect intensity without considering dynamic affective patterns. We examined these patterns in relation to daily overeating, loss of control eating (LOCE), dietary restraint, and food craving in young adults using ecological momentary assessment (EMA).Adults (N = 24) completed a 10-day EMA protocol during which they reported momentary affect and eating patterns. Generalized linear mixed-models examined each index in relation to eating variable.Higher PA instability (within-person) was associated with higher ratings of binge-eating symptoms (B = 0.15, SE = 0.06, p = 0.007). Lower NA differentiation (within-person) was associated with higher levels of food craving (B = -10.11, SE = 4.74, p = 0.033).Our results support previous findings suggesting that acute fluctuations in PA may increase risk of binge-eating symptoms. Further, inability to differentiate between momentary states of NA was associated with cravings. This study highlights the importance of examining multiple facets of NA and PA in relation to eating regulation.Trial registration: ClinicalTrials.gov identifier: NCT02945475.
The T\&S and e-SBI group will be offered two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call was offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) was offered. Also this group is expected to refer identified at-risk patients to an approved e-SBI (online screening and brief intervention) programme, which will either be country specific (where these exist) or based on the WHO e-SBI programme (Poland).
Provided are a platinum-based drug carbon nanodot and a method for preparing same and a carbon nanodot protein compound and use thereof. The platinum-based drug carbon nanodot comprises a carbon-based core having the characteristic of visible light absorption. The carbon-based core is combined with a tetravalent platinum element via a coordinate bond, and the platinum-based drug carbon nanodot can be reduced under light irradiation conditions to obtain a divalent platinum compound and a hydroxyl radical. The method for preparing the platinum-based drug carbon nanodot comprises subjecting a disubstituted aromatic compound and a tetravalent platinum compound to a solvothermal reaction to obtain the platinum-based drug carbon nanodot. Under irradiation of visible light, the carbon-based core generates hole-electron pairs. Excited-state electrons are captured by platinum (IV) to undergo a reduction reaction, which rapidly generates a Pt (II) compound with high cytotoxicity and a hydroxyl radical and reduces the pH value of cells and a tumor site, resulting in immunogenic death of cancer cells and activation of the anti-tumor immune response of the body as well while killing the cancer cells. The platinum-based drug carbon nanodot and the protein compound thereof of the present invention can serve as a high-efficiency photoactive anti-cancer drug for precision treatment of tumors.
In the detailed description we believe that it will be wise to discuss about the long-term study of the effect of GO2KA1(Chitosan oligosaccharide: oligosaccharides derived from chitosan) on pre-diabetic individuals (in addition to the postprandial blood glucose levels). In the present study, we will investigate the effects of GO2KA1 on the level of postprandial blood glucose in adult Koreans with impaired fasting glucose or impaired glucose tolerance. Postprandial blood glucose levels will be tested for 2 hours at every 30 min interval after 75g-OGTT and the experimental group will be pre-fed with 500 mg of GO2KA1. Primary outcomes will be included change in HbA1c, insulin, glycemic AUC, and lipids(total cholesterol, triglyceride, and HDL).

This clinical study will be conducted with 60 subjects after explanation and accommodation about experimental protocols and model. To test under same condition, smoking and drinking water will be completely prohibit from 1 hour before and during the experiment. At first day, control experiment will be conducted without oral take of GO2KA1 or placebo.